Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Around the world, our medicines help millions of people in their fight against such diseases as cancer, cardiovascular disease, hepatitis B, HIV/AIDS, rheumatoid arthritis and psychiatric disorders.
At Bristol-Myers Squibb, our BioPharma strategy uniquely combines the reach and resources of a major pharma company with the entrepreneurial spirit and agility of a successful biotech company. With this strategy, we focus on our customers’ needs, giving maximum priority to accelerating pipeline development, delivering sales growth and continuing to manage costs.

Research Grants 52 show all


$16.9M
2013

$5.8M
2014

$1.2M
2016

$19.6M
2017

$491.6K
2019

Publications 10,021 show all

  • 116
    Chromatography, High Pressure Liquid/methods
  • 112
    Drug Design
  • 108
    Enzyme Inhibitors/pharmacology
  • 104
    Chromatography, Liquid/methods
  • 98
    Tandem Mass Spectrometry/methods
  • 95
    Mass Spectrometry/methods
  • 91
    Antiviral Agents/pharmacology
  • 91
    Diabetes Mellitus, Type 2/drug therapy
  • 87
    Antineoplastic Agents/therapeutic use
  • 83
    Hepatitis C, Chronic/drug therapy

Patents 55,913show all

  • 14,276
    C07D - Heterocyclic compounds
  • 10,127
    A61K - Preparations for medical, dental, or toilet purposes
  • 5,362
    C07K - Peptides
  • 3,305
    C07C - Acyclic or carbocyclic compounds
  • 1,600
    C12N - Microorganisms or enzymes
  • 1,350
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 1,283
    A61F - Filters implantable into blood vessels
  • 1,175
    C07H - Sugars
  • 1,047
    C12P - Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture
  • 1,038
    A61Q - Specific use of cosmetics or similar toilet preparations

Clinical Trials 2,532show all

738Phase 2550Phase 1472Phase 3191Phase 1/Phase 2149Phase 4149Other

SEC Filings show all


271
8-K

78
10-Q

26
10-K

Contact Information

Hopewell Township, NJ
United States

SEC Form D Funding Events

DateOfferedSoldType
2008-11-17$15,510,000$15,510,000Option to Acquire, Security to be Acquired
2004-10-29Unknown Unknown Other (Paper Filing)

Key Executives

  • Bruce L.a. Carter, Ph.D.
    Executive Officer, Director
  • James A. Harper
    Director
  • Judith A. Hemberger, Ph.D.
    Director
  • David I. Hirsch, Ph.D.
    Director
  • Jonathan S. Leff
    Director
  • David H. MacCallum
    Director
  • Kurt Anker Nielsen
    Director
  • Edward E. Penhoet, Ph.D.
    Director
  • Lars Rebien Sorensen
    Director
  • Michael J. Dwyer
    Executive Officer
  • Heather L. Franklin
    Executive Officer
  • Darren R. Hamby
    Executive Officer
  • Vaughn B. Himes, Ph.D.
    Executive Officer
  • James A. Johnson
    Executive Officer
  • Nicole Onetto, M.D.
    Executive Officer
  • Suzanne M. Shema, J.D.
    Executive Officer
  • Douglas E. Williams, Ph.D.
    Executive Officer